Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Genenta Science S.p.A. Unsponsored ADR (GNTA : NSDQ)

• Company Description    Genenta Science S.p.A. is a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon(TM). Genenta Science S.p.A. is based in MILAN, Italy. Number of Employees: 13

• Price / Volume Information    Yesterday's Closing Price: $2.56 Daily Weekly Monthly 20 Day Moving Average: 1,936,946 shares Shares Outstanding: 19.15 (millions) Market Capitalization: $49.01 (millions) Beta: 0.55 52 Week High: $6.12 52 Week Low: $2.33 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -20.50% -21.79% 12 Week -26.65% -31.77% Year To Date -41.15% -49.48%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL OLGETTINA NO. 58 - MILAN,L6 20132 ITA ph: 39-02-2643-6639 fax: - investors@genenta.com http://www.genenta.com

• General Corporate Information    Officers Pierluigi Paracchi - Chief Executive Officer and Chairman Richard B. Slansky - Chief Financial Officer Todd Michael Wider - Director John Louis Cantello - Director Lauren Haeyong Chung - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 36870W100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 19.15 Most Recent Split Date: (:1) Beta: 0.55 Market Capitalization: $49.01 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.40 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - - 03/31/25 - - ROA 09/30/25 - - 06/30/25 - - 03/31/25 - - Current Ratio 09/30/25 - - 06/30/25 - 13.20 03/31/25 - - Quick Ratio 09/30/25 - - 06/30/25 - - 03/31/25 - - Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 0.75 03/31/25 - - Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.62 03/31/25 - - Debt-to-Capital 09/30/25 - - 06/30/25 - 38.41 03/31/25 - -

Powered by Zacks Investment Research ©